Blueprint Medicines (BPMC) PT Raised to $125 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 20 | New: 16
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 20 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Andrew Fein raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $125.00 (from $85.00) while maintaining a Buy rating.
You May Also Be Interested In
- Hartford Financial Services (HIG) PT Lowered to $136 at Cantor Fitzgerald
- Bloomin' Brands (BLMN) PT Raised to $11.50 at UBS
- Oshkosh (OSK) PT Lowered to $164 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
